Apyx Medical (APYX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" APYX shares.
View APYX analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price objectives for Apyx Medical's shares. Their APYX share price forecasts range from $4.50 to $10.00. On average, they predict the company's share price to reach $7.88 in the next twelve months. This suggests a possible upside of 144.6% from the stock's current price.
View analysts price targets for APYX or view top-rated stocks among Wall Street analysts.

Apyx Medical's stock was trading at $2.34 at the beginning of the year. Since then, APYX stock has increased by 37.6% and is now trading at $3.22.
View the best growth stocks for 2023 here.

Apyx Medical saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 2,850,000 shares, a drop of 16.7% from the August 15th total of 3,420,000 shares. Based on an average daily volume of 269,300 shares, the days-to-cover ratio is currently 10.6 days. Approximately 9.4% of the shares of the stock are sold short.
View Apyx Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our APYX earnings forecast.

Apyx Medical Co. (NASDAQ:APYX) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The business had revenue of $13.57 million for the quarter, compared to the consensus estimate of $14.25 million. Apyx Medical had a negative trailing twelve-month return on equity of 49.64% and a negative net margin of 34.34%.

Apyx Medical updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $59.00 million-$62.00 million, compared to the consensus revenue estimate of $59.99 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."

Apyx Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Divisadero Street Capital Management LP (6.60%), Royce & Associates LP (4.63%), Pura Vida Investments LLC (2.86%), Cowen Prime Advisors LLC (1.75%), Taylor Frigon Capital Management LLC (1.55%) and BlackRock Inc. (1.55%). Insiders that own company stock include Charles D Goodwin II and Todd Hornsby.
View institutional ownership trends.

Shares of APYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APYX stock can currently be purchased for approximately $3.22.

Apyx Medical (NASDAQ:APYX) has a market capitalization of $111.54 million and generates $44.51 million in revenue each year. The company earns $-23,180,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

The company employs 276 workers across the globe.

Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The official website for the company is www.apyxmedical.com. The company can be reached via phone at (727) 384-2323, via email at investor.relations@apyxmedical.com, or via fax at 800-323-1640.